Myelodysplastic syndrome with excess blasts is a high-risk form of bone marrow disorder where immature blood cells fail to mature properly, leaving the body vulnerable to serious complications including infections, bleeding, and potential progression to acute leukemia.
Understanding Myelodysplastic Syndrome with Excess Blasts
Myelodysplastic syndrome with excess blasts, often abbreviated as MDS-EB, represents a specific subtype within a broader group of blood disorders affecting the bone marrow. The bone marrow is the spongy material inside your bones where all blood cells are made. In healthy people, this marrow produces blood stem cells that gradually mature into the blood cells your body needs to function.[1]
When someone has MDS-EB, something goes wrong with this maturation process. The bone marrow produces too many blast cells, which are very early, immature forms of blood cells. These blasts are like unfinished products on an assembly line—they never develop into the working blood cells your body needs. Instead of maturing properly, these blast cells either die in the bone marrow or enter the bloodstream without being able to do their jobs.[2]
What makes MDS-EB particularly concerning is the high number of these immature cells. The condition is classified into two types based on how many blast cells are present. In MDS-EB1, blast cells make up 5% to 9% of cells in the bone marrow, or 2% to 4% in the blood. In MDS-EB2, the numbers are higher: 10% to 19% in the bone marrow, or 5% to 19% in the blood. The higher the blast count, the more serious the condition tends to be.[6]
Because these blast cells take up space in the bone marrow, there’s less room for healthy blood cells to develop. This crowding effect means the body doesn’t produce enough healthy red blood cells, white blood cells, or platelets. Each type of blood cell has a vital job: red blood cells carry oxygen throughout your body, white blood cells fight infections, and platelets help your blood clot when you’re injured.[4]
How Common Is MDS-EB
Myelodysplastic syndromes as a whole are relatively rare conditions. In the United States, about 4 to 4.6 cases per 100,000 people are diagnosed each year, which translates to slightly more than 10,000 people annually. Among these, MDS-EB represents one specific subtype, though exact numbers for this particular form are not widely reported.[4][9]
Age plays a significant role in who develops these conditions. The vast majority of people diagnosed with myelodysplastic syndromes, including MDS-EB, are older adults. The median age at diagnosis is approximately 70 years, and the condition is far more common in people over 60. According to some estimates, between 22 and 45 per 100,000 people over the age of 70 have some form of MDS. This means as our population ages, we’re likely to see more cases diagnosed.[3][6]
While MDS can occur in younger people—even children as young as 2 years old have been reported—these cases are quite rare. The disease doesn’t discriminate completely, but it does show certain patterns. Men are affected slightly more often than women. The condition also appears to be more common in White individuals compared to other racial groups.[9]
Approximately 20,000 new patients are diagnosed with myelodysplastic syndromes each year in the United States. As life expectancy continues to increase globally, the number of people living with these conditions is expected to rise. This makes understanding and managing MDS-EB increasingly important for healthcare systems worldwide.[6]
What Causes MDS-EB
The exact cause of MDS-EB is often unknown, which can be frustrating for patients and their families. In many cases, doctors cannot pinpoint a specific reason why someone develops this condition. However, researchers have identified several factors that can damage the bone marrow and lead to the development of MDS-EB.[6]
One well-established cause is previous cancer treatment. People who have undergone certain types of chemotherapy or radiation therapy for other cancers are at increased risk. This is sometimes called treatment-related MDS or secondary MDS. The damage from these powerful cancer treatments can affect the DNA in bone marrow cells, causing them to malfunction. This type of MDS can develop anywhere from 1 to 15 years after the original cancer treatment.[3][17]
Some genetic conditions increase the risk of developing MDS-EB. People born with certain inherited disorders that affect their DNA may be more vulnerable to developing this condition. While these cases are less common, they demonstrate that genetic factors can play a role in the disease’s development.[6]
Environmental exposures may also contribute. Some people develop MDS after exposure to certain chemicals, particularly in workplace settings. Smoking has been linked to an increased risk of developing myelodysplastic syndromes as well. These environmental factors can cause changes in the DNA of bone marrow cells over time.[6][17]
At the cellular level, MDS-EB involves specific changes in chromosomes and genes. Many people with this condition have chromosome abnormalities visible under a microscope. Common changes include deletions (loss of parts) of chromosomes 5, 7, or 20, complete loss of chromosome 5 or 7, or an extra copy of chromosome 8. Gene mutations are also frequently found, including changes in genes called SF3B1 and TP53.[5]
These genetic changes disrupt the normal process by which stem cells mature into functional blood cells. Instead of following the usual development pathway, the cells become stuck in an immature state or die prematurely. This is what leads to the accumulation of blast cells and the shortage of healthy blood cells that characterize MDS-EB.[3]
Who Is at Higher Risk
Understanding risk factors can help identify people who might benefit from closer monitoring, though having risk factors doesn’t mean someone will definitely develop MDS-EB. Age is the most significant risk factor. The condition is uncommon in young adults and rare in children, but risk increases substantially after age 60. People over 70 face the highest risk of developing any form of myelodysplastic syndrome.[6]
People who have received cancer treatment in the past face elevated risk. Those who were treated with certain chemotherapy drugs or radiation therapy should be aware of this possibility, even if many years have passed since their treatment. Children treated for acute lymphocytic leukemia, for example, may develop treatment-related MDS later in life.[17]
Smoking represents a modifiable risk factor. People who smoke or have smoked in the past have a higher likelihood of developing myelodysplastic syndromes compared to those who have never smoked. This is one risk factor that people can address through lifestyle changes.[6]
Occupational exposures matter as well. People who work with certain chemicals or in industries where they might be exposed to substances that affect bone marrow function may face increased risk. This includes some industrial settings where workers come into contact with chemicals that can damage DNA or bone marrow cells.[3]
Genetic factors play a role in some cases. People born with certain genetic syndromes that increase cancer susceptibility may be more vulnerable to developing MDS-EB. Family history, while not as strong a risk factor as in some other cancers, may occasionally be relevant. Men appear to be at slightly higher risk than women, though the reasons for this difference aren’t entirely clear.[9]
Recognizing the Symptoms
One of the challenging aspects of MDS-EB is that many people don’t experience obvious symptoms in the early stages. The condition often develops slowly, and initial signs can be subtle or easily mistaken for normal aging or other common health problems. This is why some cases are discovered during routine blood tests done for other reasons.[1]
As the condition progresses and healthy blood cell counts drop, symptoms become more noticeable. The specific symptoms a person experiences depend largely on which types of blood cells are most affected. Because MDS-EB typically causes low levels of at least two types of blood cells, people often experience multiple symptoms.[6]
When red blood cell counts are low—a condition called anemia—people typically feel very tired and weak. This isn’t the ordinary tiredness that improves with a good night’s sleep. It’s a profound fatigue that makes even simple daily activities feel exhausting. People with anemia may also notice they become short of breath more easily, even when doing things that never bothered them before, like climbing stairs or walking short distances. They might appear unusually pale, with lighter-than-normal skin color.[1][14]
Low white blood cell counts, called leukopenia or neutropenia, make it harder for the body to fight off infections. People may notice they’re getting sick more often, or that infections last longer than usual. They might develop fevers frequently or struggle to recover from illnesses that would normally clear up quickly. Even minor infections can become problematic when white blood cell counts are very low.[1][6]
When platelet counts drop—a condition called thrombocytopenia—bleeding and bruising become concerns. People might notice they bruise very easily, developing bruises from minor bumps that wouldn’t normally cause bruising. They may experience nosebleeds or bleeding gums, and small cuts might bleed for longer than expected. Some people develop small red or purple spots under their skin called petechiae, which are actually tiny areas of bleeding just beneath the skin’s surface.[1][14]
In some cases, people with MDS-EB may notice firm masses in their neck, which could indicate that the disease is affecting lymph nodes. Others might experience changes in their voice if nerves are affected. These symptoms are less common but can occur as the disease progresses.[6]
It’s important to note that these symptoms are not specific to MDS-EB—they can occur with many other health conditions. However, if symptoms persist or worsen, especially combinations of tiredness, frequent infections, and unusual bleeding or bruising, it’s important to consult with a healthcare provider for proper evaluation.[1]
Prevention Strategies
Because the exact cause of most cases of MDS-EB is unknown, there’s no guaranteed way to prevent the condition. However, understanding risk factors can help people make informed choices that might reduce their risk. This is particularly important because some risk factors can be modified through lifestyle changes or medical decisions.[3]
For people who smoke, quitting represents one of the most impactful preventive steps. Smoking has been linked to an increased risk of myelodysplastic syndromes, and stopping this habit can reduce that risk. While quitting smoking benefits health in numerous ways, its potential role in lowering MDS risk adds another reason to consider cessation programs or support.[6]
People who work in environments where they might be exposed to chemicals that affect bone marrow should take workplace safety seriously. Following safety protocols, using protective equipment, and minimizing exposure to potentially harmful substances can help protect bone marrow health. Employers and workers should be aware of and follow occupational safety guidelines for handling such materials.[3]
For individuals undergoing cancer treatment, discussions with oncologists about the long-term risks of different treatment options can be valuable. While the immediate goal is always to treat the current cancer effectively, awareness of potential late effects, including the risk of developing treatment-related MDS, can inform treatment decisions when multiple effective options exist. This doesn’t mean avoiding necessary cancer treatment, but rather being informed about potential future risks.[17]
Regular medical check-ups become particularly important for people at higher risk, such as those who have received chemotherapy or radiation in the past. Routine blood tests can sometimes detect early changes in blood cell counts before symptoms develop. Early detection doesn’t prevent the disease, but it can allow for earlier intervention and potentially better outcomes.[3]
People with genetic conditions that increase cancer risk should work closely with their healthcare providers to develop appropriate screening and monitoring plans. Genetic counseling may be helpful for understanding individual risk and making informed healthcare decisions.[6]
How the Body Changes in MDS-EB
To understand what goes wrong in MDS-EB, it helps to know what normally happens in healthy bone marrow. In a healthy person, the bone marrow continuously produces blood stem cells, which are immature cells with the potential to become any type of blood cell. These stem cells go through several stages of development, gradually maturing into red blood cells, white blood cells, or platelets. At each stage, the cells become more specialized and closer to their final, functional form.[7]
In MDS-EB, this carefully orchestrated process breaks down. The problem begins at the level of the blood stem cells themselves, which become abnormal due to genetic changes or damage. These defective stem cells produce blast cells that cannot complete the maturation process. Instead of continuing to develop into healthy, functional blood cells, the blasts either die in the bone marrow or enter the bloodstream in their immature, non-functional state.[3]
This failure in blood cell production is called ineffective hematopoiesis. Hematopoiesis is the medical term for blood cell production, and “ineffective” means the process isn’t working properly. The bone marrow may actually appear quite active—sometimes even more active than normal—but despite all this activity, it’s not producing enough healthy, mature blood cells. It’s like a factory running at full speed but producing defective products that can’t be used.[3]
The accumulation of blast cells creates a crowding problem in the bone marrow. Because these immature cells take up physical space and use resources, there’s less room and fewer resources available for the development of healthy blood cells. This crowding effect contributes to the low blood cell counts that cause symptoms.[2]
At the microscopic level, pathologists examining bone marrow from someone with MDS-EB see abnormalities in cell appearance and structure. The cells may be oddly shaped or sized, a condition called dysplasia. Red blood cells might appear larger than normal (megaloblastoid), white blood cells might have abnormal granules or unusual nuclear shapes, and platelets might be unusually small or large. These physical abnormalities reflect the underlying genetic problems affecting cell development.[9]
The genetic changes underlying MDS-EB involve both chromosomes and specific genes within cells. Chromosomal abnormalities can be seen under a microscope, such as missing pieces of chromosomes or extra copies of chromosomes. At a more detailed level, mutations in specific genes affect how cells grow, divide, and mature. These genetic problems accumulate over time, and in some cases, additional mutations develop that push the disease toward becoming acute leukemia.[5]
The progression from MDS-EB to acute myeloid leukemia occurs when blast cells accumulate to even higher levels—20% or more in the blood or bone marrow. At this point, the disease is reclassified as leukemia. This transition represents a critical change because acute leukemia is more aggressive and requires different treatment approaches. Between 5% and 29% of MDS-EB cases progress to acute leukemia, with the risk being higher in MDS-EB2 compared to MDS-EB1.[6][9]
The body’s attempts to compensate for low blood cell counts can create additional problems. For example, when red blood cell counts drop, the body tries to respond by increasing production signals, but the defective bone marrow cannot respond effectively. This mismatch between the body’s needs and the bone marrow’s capacity creates the chronic symptoms people experience.[3]